Physician profile
Colt Kennington
NPI 1386106268
$1,146.70
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $44.90 · 2023: $264 · 2024: $838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,101.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $229.78 | 2023-2024 | |
| Neurocrine Biosciences, INC. | $192.72 | 2023-2024 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $150.42 | 2023-2024 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $101.15 | 2023-2024 | Caplyta |
| Tris Pharma INC | $74.85 | 2023-2024 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $73.90 | 2023-2024 | Invega Sustenna, Spravato |
| Lundbeck LLC | $56.75 | 2023-2024 | Rexulti |
| Alkermes, INC. | $51.44 | 2023-2024 | Aristada, Lybalvi, Vivitrol |
| Corium, LLC | $44.61 | 2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $37.54 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $30.43 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $22.25 | 2024 | |
| Vanda Pharmaceuticals INC. | $18.98 | 2024 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $18.20 | 2024 | Austedo Xr |
| Indivior INC. | $14.74 | 2023 | Perseris |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $14.47 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.47 | 2023 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colt Kennington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.